Keywords
Abstract
Polyendocrine metabolic ovarian syndrome (PMOS) is a common endocrine condition in women of reproductive age and a leading cause of anovulatory infertility. Its clinical and metabolic heterogeneity necessitates an individualized treatment strategy.
Personalized management should take into account the PMOS phenotype, metabolic profile, ovarian reserve, age, duration of infertility, and reproductive priorities.
References
Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. https://doi.org/10.1210/clinem/dgad463
Sparić R, Andjić M, Rakić A, Bjekić-Macut J, Livadas S, Kontić-Vučinić O, Mastorakos G, Macut D. Insulin-sensitizing agents for infertility treatment in woman with polycystic ovary syndrome: a narrative review of current clinical practice. Hormones (Athens). 2024;23(1):49-58. https://doi.org/10.1007/s42000-023-00494-y